Drug intelligence / Profile preview

NHWD-870

Development stage
Phase 2
Lead developer
Zhejiang Wenda Pharmaceutical Technology
Modality
Small Molecules
Administration
Oral
01

Overview

NHWD-870 is a potent, orally bioavailable bromodomain and extra-terminal (BET) inhibitor that exhibits selectivity for bromodomain containing 4 (BRD4). It was developed for anti-cancer potential and is more potent than clinical stage BET inhibitors such as birabresib and molibresib. NHWD-870 binds to bromodomains of BRD2, BRD3, BRD4 (IC50=2.7 nM), and BRDT. It has demonstrated efficacy in reducing tumor growth in multiple mouse models of cancers, including lung and ovarian tumors, lymphoma, and melanoma. Beyond oncology applications, research has shown potential applications in psoriasis treatment and as a male contraceptive.

Other names
NHWD-870 HClNHWD870 HClNHWD 870 HCl
02

Targets

BRD2 (Bromodomain-containing protein 2)BRD3 (Bromodomain-containing protein 3)BRD4 (Bromodomain-containing protein 4)BRDT (Bromodomain testis-specific protein)KCNH2 (Voltage-gated potassium channel subfamily H member 2)IRF7 (Interferon regulatory factor 7)

Beyond the preview

Go deeper on NHWD-870.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NHWD-870.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call